Liao, C.-C.C.-C.LiaoHuang, H.-K.H.-K.HuangChen, Y.-Z.Y.-Z.ChenNIEN-TSU HUANG2021-05-052021-05-05202010846999https://www.scopus.com/inward/record.url?eid=2-s2.0-85083279843&partnerID=40&md5=7b732db2e9c19866d8f07625c7494329https://scholars.lib.ntu.edu.tw/handle/123456789/559124To ensure appropriate antibiotics treatment, antibiotic susceptibility test (AST) is a common method in clinical therapies for selecting proper antibiotic treatment and preventing misuse or overuse of antibiotics. However, the existing method still undergoes several obstacles, such as time-consuming, label-intensive process and lack of accuracy. Here, we develop a microfluidics platform integrating microwell with surface-enhanced Raman scattering (SERS) technology for low concentration bacteria encapsulation followed by in situ AST. The microwell can greatly increase the effective bacteria concentration and SERS technology can enable a rapidly and highly specific molecular detection from bacteria-secreted metabolites. Combing above features, the microwell-SERS platform can achieve label-free, low concentration (103 CFU/mL) bacteria detection and has the potential to provide AST reference in clinical diagnosis. © 2020 IEEE.Antibiotic susceptibility test; Microfluidics; Microwell; Surface-enhance Raman scatteringAntibiotics; Bacteria; Diagnosis; Mechanics; MEMS; Metabolites; Microchannels; Microfluidics; Raman scattering; Surface testing; Antibiotic susceptibility tests; Antibiotic treatment; Bacteria concentrations; Bacteria detection; Bacteria enrichment; Clinical diagnosis; Molecular detection; Surface enhanced Raman Scattering (SERS); Surface scatteringconference paper10.1109/MEMS46641.2020.90564352-s2.0-85083279843